Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1989 Sep 30;299(6703):819–821. doi: 10.1136/bmj.299.6703.819

Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.

P Portegies 1, J de Gans 1, J M Lange 1, M M Derix 1, H Speelman 1, M Bakker 1, S A Danner 1, J Goudsmit 1
PMCID: PMC1837716  PMID: 2510843

Abstract

OBJECTIVE--To assess the incidence of the AIDS dementia complex and the presence of HIV I p24 antigen in cerebrospinal fluid in relation to zidovudine treatment. DESIGN--Retrospective study of a consecutive series of patients with AIDS from 1982 to 1988. SETTING--An academic centre for AIDS. PATIENTS--196 Patients with AIDS and neurological symptoms examined from 1982 to 1988. INTERVENTIONS--Zidovudine treatment, which was introduced to The Netherlands on 1 May 1987 for patients with severe symptoms of HIV infection (Centers for Disease Control groups IVA, B, C, and D). MAIN OUTCOME MEASURES--Diagnosis of AIDS dementia complex and presence of HIV I p24 antigen in cerebrospinal fluid. RESULTS--The AIDS dementia complex was diagnosed in 40 of the 196 (20%) patients with AIDS. Thirty eight of 107 patients with AIDS (36%) not taking zidovudine developed the AIDS dementia complex compared with two of the 89 (2%) taking the drug (p less than 0.00001). The incidence of the AIDS dementia complex increased to 53% in the first half of 1987, after the introduction of zidovudine in May 1987, decreasing to 10% in the second half of 1987 and to 3% in 1988. Dementia was diagnosed before definition of the AIDS dementia complex (1986) according to DSM-III criteria and there was good agreement between diagnosis before and after 1986. Sixteen of 61 samples of cerebrospinal fluid (26%) from patients with AIDS (10 with the AIDS dementia complex) not taking zidovudine were positive for HIV I p24 antigen, whereas none of 37 cerebrospinal fluid samples from patients with AIDS (two with the AIDS dementia complex) taking zidovudine were positive. CONCLUSIONS--The incidence of AIDS dementia complex in patients with AIDS declined after the introduction of systematic treatment with zidovudine; the AIDS dementia complex might be prevented by inhibiting viral replication in the central nervous system.

Full text

PDF
819

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dournon E., Matheron S., Rozenbaum W., Gharakhanian S., Michon C., Girard P. M., Perronne C., Salmon D., De Truchis P., Leport C. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet. 1988 Dec 3;2(8623):1297–1302. doi: 10.1016/s0140-6736(88)92903-0. [DOI] [PubMed] [Google Scholar]
  2. Epstein L. G., Goudsmit J., Paul D. A., Morrison S. H., Connor E. M., Oleske J. M., Holland B. Expression of human immunodeficiency virus in cerebrospinal fluid of children with progressive encephalopathy. Ann Neurol. 1987 Apr;21(4):397–401. doi: 10.1002/ana.410210413. [DOI] [PubMed] [Google Scholar]
  3. Epstein L. G., Sharer L. R., Gajdusek D. C. Hypothesis: AIDS encephalopathy is due to primary and persistent infection of the brain with a human retrovirus of the lentivirus subfamily. Med Hypotheses. 1986 Sep;21(1):87–96. doi: 10.1016/0306-9877(86)90065-4. [DOI] [PubMed] [Google Scholar]
  4. Fauci A. S. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 1988 Feb 5;239(4840):617–622. doi: 10.1126/science.3277274. [DOI] [PubMed] [Google Scholar]
  5. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  6. Goudsmit J., de Wolf F., Paul D. A., Epstein L. G., Lange J. M., Krone W. J., Speelman H., Wolters E. C., Van der Noordaa J., Oleske J. M. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet. 1986 Jul 26;2(8500):177–180. doi: 10.1016/s0140-6736(86)92485-2. [DOI] [PubMed] [Google Scholar]
  7. Koenig S., Gendelman H. E., Orenstein J. M., Dal Canto M. C., Pezeshkpour G. H., Yungbluth M., Janotta F., Aksamit A., Martin M. A., Fauci A. S. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986 Sep 5;233(4768):1089–1093. doi: 10.1126/science.3016903. [DOI] [PubMed] [Google Scholar]
  8. Lange J. M., Paul D. A., Huisman H. G., de Wolf F., van den Berg H., Coutinho R. A., Danner S. A., van der Noordaa J., Goudsmit J. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) 1986 Dec 6;293(6560):1459–1462. doi: 10.1136/bmj.293.6560.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lee M. R., Ho D. D., Gurney M. E. Functional interaction and partial homology between human immunodeficiency virus and neuroleukin. Science. 1987 Aug 28;237(4818):1047–1051. doi: 10.1126/science.3039662. [DOI] [PubMed] [Google Scholar]
  10. Marshall D. W., Brey R. L., Cahill W. T., Houk R. W., Zajac R. A., Boswell R. N. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol. 1988 Sep;45(9):954–958. doi: 10.1001/archneur.1988.00520330032007. [DOI] [PubMed] [Google Scholar]
  11. Navia B. A., Cho E. S., Petito C. K., Price R. W. The AIDS dementia complex: II. Neuropathology. Ann Neurol. 1986 Jun;19(6):525–535. doi: 10.1002/ana.410190603. [DOI] [PubMed] [Google Scholar]
  12. Navia B. A., Jordan B. D., Price R. W. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986 Jun;19(6):517–524. doi: 10.1002/ana.410190602. [DOI] [PubMed] [Google Scholar]
  13. Pizzo P. A., Eddy J., Falloon J., Balis F. M., Murphy R. F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. doi: 10.1056/NEJM198810063191401. [DOI] [PubMed] [Google Scholar]
  14. Portegies P., Epstein L. G., Hung S. T., de Gans J., Goudsmit J. Human immunodeficiency virus type 1 antigen in cerebrospinal fluid. Correlation with clinical neurologic status. Arch Neurol. 1989 Mar;46(3):261–264. doi: 10.1001/archneur.1989.00520390027010. [DOI] [PubMed] [Google Scholar]
  15. Portegies P., de Gans J., Lange J. M., Derix M. M., Speelman H., Bakker M., Danner S. A., Goudsmit J. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ. 1989 Sep 30;299(6703):819–821. doi: 10.1136/bmj.299.6703.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Price R. W., Brew B., Sidtis J., Rosenblum M., Scheck A. C., Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988 Feb 5;239(4840):586–592. doi: 10.1126/science.3277272. [DOI] [PubMed] [Google Scholar]
  17. Ratner L., Polmar S. H., Paul N., Ruddle N. Cytotoxic factors secreted by cells infected by human immunodeficiency virus type I. AIDS Res Hum Retroviruses. 1987 Summer;3(2):147–155. doi: 10.1089/aid.1987.3.147. [DOI] [PubMed] [Google Scholar]
  18. Schmitt F. A., Bigley J. W., McKinnis R., Logue P. E., Evans R. W., Drucker J. L. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1988 Dec 15;319(24):1573–1578. doi: 10.1056/NEJM198812153192404. [DOI] [PubMed] [Google Scholar]
  19. Sharer L. R., Cho E. S., Epstein L. G. Multinucleated giant cells and HTLV-III in AIDS encephalopathy. Hum Pathol. 1985 Aug;16(8):760–760. doi: 10.1016/s0046-8177(85)80245-8. [DOI] [PubMed] [Google Scholar]
  20. Shaw G. M., Harper M. E., Hahn B. H., Epstein L. G., Gajdusek D. C., Price R. W., Navia B. A., Petito C. K., O'Hara C. J., Groopman J. E. HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science. 1985 Jan 11;227(4683):177–182. doi: 10.1126/science.2981429. [DOI] [PubMed] [Google Scholar]
  21. Snider W. D., Simpson D. M., Nielsen S., Gold J. W., Metroka C. E., Posner J. B. Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol. 1983 Oct;14(4):403–418. doi: 10.1002/ana.410140404. [DOI] [PubMed] [Google Scholar]
  22. Wiley C. A., Schrier R. D., Nelson J. A., Lampert P. W., Oldstone M. B. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7089–7093. doi: 10.1073/pnas.83.18.7089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Yarchoan R., Berg G., Brouwers P., Fischl M. A., Spitzer A. R., Wichman A., Grafman J., Thomas R. V., Safai B., Brunetti A. Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet. 1987 Jan 17;1(8525):132–135. doi: 10.1016/s0140-6736(87)91968-4. [DOI] [PubMed] [Google Scholar]
  24. Yarchoan R., Klecker R. W., Weinhold K. J., Markham P. D., Lyerly H. K., Durack D. T., Gelmann E., Lehrman S. N., Blum R. M., Barry D. W. Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986 Mar 15;1(8481):575–580. doi: 10.1016/s0140-6736(86)92808-4. [DOI] [PubMed] [Google Scholar]
  25. de Gans J., Lange J. M., Derix M. M., de Wolf F., Eeftinck Schattenkerk J. K., Danner S. A., Ongerboer de Visser B. W., Cload P., Goudsmit J. Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS. 1988 Feb;2(1):37–40. doi: 10.1097/00002030-198802000-00006. [DOI] [PubMed] [Google Scholar]
  26. de Wolf F., Lange J. M., Goudsmit J., Cload P., de Gans J., Schellekens P. T., Coutinho R. A., Fiddian A. P., van der Noordaa J. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet. 1988 Feb 20;1(8582):373–376. doi: 10.1016/s0140-6736(88)91179-8. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES